Dear ,

In the current issue of the OncoWuXi Newsletter, we share with you the update on our service and newly established capabilities.

OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of the WuXi AppTec Research Service Division (RSD), our top-notch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases, and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.
WuXi AppTec Single Cell RNA Sequencing Service

(1) Workflow, quality control and data analysis

(2) Case studies:
  • Visualization of cell types and biomarkers of interest via 2D plots
  • Detection of treatment-induced change of immune cells
  • Detection of treatment-induced gene expression alteration in tumor cells
  • Discovery of potential key ligand-receptor pairs functioning in the tumor microenvironment
  • Exploration on large-scale chromosomal copy number alteration

WuXi AppTec STING Pathway Related Service

(1)  In vitro STING pathway related functional assays
  • Protein-based binding of SR-717 to the recombinant STING-DCL8 protein by Thermal Shift assay
  • STING activation by STING agonist (STING-1) in human PBMCs or THP1 cells, using IFN-β as a readout
  • STING activation by STING agonist (STING-1) in THP1-IFN-β-Luc reporter cells
(2) In vivo anti-tumor efficacy study of STING agonist in B16F10, CT26, and 4T1 syngeneic models
(3) Immune cell activation analysis in tumor and spleen in B16F10 syngeneic model post STING agonist treatment

Translational Oncology
WuXi AppTec AMG510-induced Resistant Model of MIA PaCa-2

(1)  Introduction of resistance to KRASG12C-targeted inhibitors

(2)  Development of AMG510 resistant MIA PaCa-2 CDX model with validation data both in vitro and in vivo

Targeted Oncology
WuXi AppTec Genetically Engineered Cell Related Service

(1)  Genetically engineered Ba/F3 cell lines carrying EGFR mutations
  • Ba/F3 EGFR exon 19 deletion
  • Ba/F3 EGFR exon 19 del/T790M
  • Ba/F3 EGFR exon 19 del/T790M/C797S
  • Ba/F3 EGFR L858R
  • Ba/F3 EGFR L858R/T790M
  • Ba/F3 EGFR L858R/C797S
  • Ba/F3 EGFR L858R/T790M/C797S
  • Ba/F3 EGFR exon 20_V769_D770insASV
  • Ba/F3 EGFR exon 20_D770_N771insSVD
  • Ba/F3 EGFR exon 20_H773_V774insNPH
  • Validated with Osimertinib, Erlotinib, Gefitinib, CO-1686, Afatinib, Dacomitinib, Brigatinib, and Poziotinib in vitro or in vivo

(2)  Genetically engineered Ba/F3 cell lines carrying RET mutations
  • Ba/F3 KIF5B-RET WT
  • Ba/F3 KIF5B-RET V804L
  • Ba/F3 KIF5B-RET V804M
  • Ba/F3 KIF5B-RET G810R
  • Ba/F3 KIF5B-RET G810S
  • Ba/F3 CCDC6-RET WT
  • Ba/F3 CCDC6-RET V804M
  • Ba/F3 CCDC6-RET V804L
  • Validated with Cabozatinib, Vandetanib, Lenvatinib, Sunitinib, Regorafenib, Pralsetinib, Ponatinib, Sorafenib, and LOXO-292 in vitro or in vivo

(3)  Genetically engineered Ba/F3 cell lines carrying FLT3 mutations
  • Ba/F3 FLT3-ITD
  • Ba/F3 FLT3-ITD F691L
  • Ba/F3 FLT3-ITD D835Y
  • Validated with Ponatinib, Sorafenib, Sunitinib, and AC220 in vitro or in vivo

(4)  Genetically engineered Ba/F3 cell lines carrying ROS1 mutations
  • Ba/F3 CD74-ROS1 (exon 32)
  • Ba/F3 CD74-ROS1 (exon 32) G2032R
  • Ba/F3 CD74-ROS1 (exon 34)
  • Ba/F3 CD74-ROS1 (exon 34) G2032R
  • Ba/F3 CD74-ROS1 (exon 32) L2026M
  • Ba/F3 CD74-ROS1 (exon 34) L2026M
  • Validated with Crizotinib, TPX-0005, Alectinib, and Brigatinib in vitro or in vivo

We sincerely appreciate your interest, time and support, and would like to hear your feedback so that we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns. 
Best regards,
WuXi AppTec OncoWuXi Team